Vitality Watch

⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.

Mentioned 2× · first seen 07-oct-2026 · last seen 07-oct-2026

NLRP3 Inflammasome Inhibitors (MCC950)

Current understanding

To be populated as evidence accumulates.

Evidence log

  • 2026-09-28 — Functional Shift of NLRP3 Inflammasome Activity in Aged Macrophages.: Preclinical macrophage study reframes NLRP3 in aged cells as a regulator of the apoptosis–senescence balance rather than a cytokine driver; MCC950 blockade reduced apoptosis but increased senescent cell burden (animal-model / cell-level preclinical). [animal-model] (novelty: 3)

Open questions

Related

Contributing findings

pubmed review
Beyond Inflammation: The NLRP3 Inflammasome as a Cellular and Mechanical Hub of Vascular Remodeling in Hypertension.
05-oct-2026 novelty 2 per-area 3 introduces
pubmed preclinical animal-model
Functional Shift of NLRP3 Inflammasome Activity in Aged Macrophages.
28-sep-2026 novelty 3 per-area 3 strengthens

build build 880 · 2bcef25 · 2026-11-18